Bone Turnover Markers, n-Terminal Propeptide of Type I Procollagen and Tartrate-Resistant Acid Phosphatase Type 5b, for Predicting Castration Resistance in Prostate Cancer

被引:1
|
作者
Kano, Hiroshi [1 ]
Izumi, Kouji [1 ]
Nakagawa, Ryunosuke [1 ]
Toriumi, Ren [1 ]
Aoyama, Shuhei [1 ]
Kamijima, Taiki [1 ]
Makino, Tomoyuki [1 ]
Naito, Renato [1 ]
Iwamoto, Hiroaki [1 ]
Yaegashi, Hiroshi [1 ]
Kawaguchi, Shohei [1 ]
Shigehara, Kazuyoshi [1 ]
Nohara, Takahiro [1 ]
Mizokami, Atsushi [1 ]
机构
[1] Kanazawa Univ, Grad Sch Med Sci, Dept Integrat Canc Therapy & Urol, 13-1 Takara Machi, Ishikawa 9208640, Japan
关键词
P1NP; TRACP-5b; castration-resistant prostate cancer; PROGRESSION; METASTASIS; CELLS;
D O I
10.3390/biomedicines12020292
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bone is a common site of prostate cancer metastasis. Bone turnover markers n-terminal propeptide of type I procollagen (P1NP) and tartrate-resistant acid phosphatase type 5b (TRACP-5b) are highly sensitive to bone remodeling activity. However, their prognostic significance as markers of prostate cancer is unknown. This study retrospectively examined the usefulness of P1NP and TRACP-5b as prognostic biomarkers. Castration-resistant prostate cancer recurrence-free survival (CFS) was estimated using the Kaplan-Meier method. A predictive model for CFS was constructed using multivariate analysis. This study enrolled 255 patients diagnosed with prostate cancer at Kanazawa University Hospital. The median follow-up was 115.1 months. Patients with both high serum P1NP and TRACP-5b levels, defined as having a poor bone turnover category (BTC), had significantly shorter CFS. Multivariate analysis identified Gleason score, metastasis, and BTC poor as predictors for castration resistance in prostate cancer. Using these three factors, a prognostic model was established, categorizing patients into low-risk (no or one factor) and high-risk (two or three factors) groups. In the low-risk group, the median CFS was not reached, contrasting with 19.1 months in the high-risk group (hazard ratio, 32.23, p < 0.001). Combining P1NP and TRACP-5b may better predict castration resistance.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism
    Lu, Kuo-Cheng
    Tseng, Chin-Feng
    Wu, Chia-Chao
    Yeung, Lai-King
    Chen, Jin-Shuen
    Chao, Tsu-Yi
    Janckila, Anthony J.
    Yam, Lung T.
    Chu, Pauling
    BLOOD PURIFICATION, 2006, 24 (5-6) : 423 - 430
  • [32] The biomarker tartrate-resistant acid phosphatase 5b (TRACP5b) A marker of bone metabolism
    Oremek, G. M.
    Passek, K.
    Bendels, M.
    Wanke, E. M.
    Ohlendorf, D.
    ZENTRALBLATT FUR ARBEITSMEDIZIN ARBEITSSCHUTZ UND ERGONOMIE, 2021, 71 (05): : 243 - 247
  • [33] Identification and Functional Analysis of Tartrate-Resistant Acid Phosphatase Type 5b (TRAP5b) in Oreochromis niloticus
    Lei, Yang
    Fu, Shengli
    Yang, Yanjian
    Chen, Jianlin
    Li, Bingxi
    Guo, Zheng
    Ye, Jianmin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (08)
  • [34] Effect of zoledronic acid on tartrate-resistant acid phosphatase isoform 5b (TRAP-5b) and other bone markers in lung cancer patients with bone metastasis
    Zhang, W.
    Rabinowits, G.
    Janckila, A. J.
    Yam, L.
    Handler, F. J.
    Laber, D. A.
    Li, C.
    Kloecker, G. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases
    Mose, S
    Menzel, C
    Kurth, AA
    Obert, K
    Ramm, U
    Eberlein, K
    Boettcher, HD
    Pichlmeier, U
    ANTICANCER RESEARCH, 2005, 25 (6C) : 4639 - 4645
  • [36] Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis
    Wu, Yi-Ying
    Janckila, Anthony J.
    Ku, Chih-Hung
    Yu, Cheng-Ping
    Yu, Jyh-Cherng
    Lee, Su-Hui
    Liu, Hsin-Yi
    Yam, Lung T.
    Chao, Tsu-Yi
    BMC CANCER, 2010, 10
  • [37] Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis
    Yi-Ying Wu
    Anthony J Janckila
    Chih-Hung Ku
    Cheng-Ping Yu
    Jyh-Cherng Yu
    Su-Hui Lee
    Hsin-Yi Liu
    Lung T Yam
    Tsu-Yi Chao
    BMC Cancer, 10
  • [38] Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption
    Hannon, RA
    Clowes, JA
    Eagleton, AC
    Al Hadari, A
    Eastell, R
    Blumsohn, A
    BONE, 2004, 34 (01) : 187 - 194
  • [39] Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients
    Chao, TY
    Yu, JC
    Ku, CH
    Chen, MM
    Lee, SH
    Janckila, AJ
    Yam, LT
    CLINICAL CANCER RESEARCH, 2005, 11 (02) : 544 - 550
  • [40] Evaluation of a novel immunoassay for serum tartrate-resistant acid phosphatase type 5b activity in hormone replacement therapy
    Igarashi, Y
    Mochizuki, Y
    Miura, T
    Ohashi, T
    Sasagawa, K
    Katayama, K
    Inaba, N
    Matsuzaki, S
    BONE, 2003, 32 (05) : S179 - S179